Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan (Dato-DXd) in combination with programmed cell death-ligand 1 inhibitor, durvalumab, as the first sequence of therapy in the I-SPY2.2 phase 2 neoadjuvant sequential multiple assignment randomization trial for high-risk stage 2/3 breast cancer.

Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes.

Neuromuscular Activity and Muscular Oxygenation Through Different Movement Cadences During In-water and On-land Knee Extension Exercise.

Chien, K-Y, Kan, N-W, Liao, Y-H, Lin, Y-L, Lin, C-L, and Chen, W-C. Neuromuscular activity and muscular oxygenation through different movement cadences during in-water and on-land knee extension exercise. J Strength Cond Res 31(3): 750-757, 2017-The purpose of this study was to determine the influence of various knee extension exercise cadences on neuromuscular activation and hemodynamic properties of the quadriceps muscle in water and on land.